TRT Side Effects: What the Research Actually Shows

1. Introduction

testosterone replacement therapy (TRT) has emerged as a widely discussed and increasingly utilized treatment for men experiencing symptomatic testosterone deficiency, often referred to as hypogonadism. While its benefits in improving energy, libido, mood, and body composition are well-documented, TRT is also a subject of considerable debate, often fueled by misinformation and outdated research regarding its potential side effects. The internet abounds with anecdotal accounts and sensationalized claims that frequently misrepresent the actual clinical evidence.

This article aims to provide a comprehensive, evidence-based review of TRT side effects, drawing primarily from large-scale clinical trials, meta-analyses, and authoritative medical guidelines. Our objective is to separate myth from reality, offering a balanced perspective on what the most robust scientific data actually shows regarding the risks associated with TRT. By examining the nuances of each potential side effect, we hope to equip individuals and healthcare providers with accurate information to make informed decisions about testosterone therapy.

2. cardiovascular and testosterone health Risk: The TRAVERSE Trial Changed Everything

For many years, the most significant and contentious debate surrounding TRT revolved around its potential impact on cardiovascular health. Early observational studies and small trials, often with methodological limitations, raised concerns about an increased risk of cardiovascular events, including heart attack and stroke.

The 2010 TOM (Testosterone in Older Men) trial was a small, short-term study that was prematurely halted due to an imbalance of cardiovascular events in the testosterone group, sparking initial alarm. This was followed by other studies and meta-analyses that, despite their flaws, contributed to a climate of caution. Consequently, in 2014, the U.S. Food and Drug Administration (FDA) issued a warning requiring labeling changes for all approved testosterone products, stating that they "may increase the risk of heart attack and stroke." This warning, though based on limited evidence at the time, significantly impacted public perception and physician prescribing habits.

The scientific community recognized the urgent need for a large, well-designed, placebo-controlled trial to definitively address these cardiovascular safety concerns. This led to the landmark TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Safety in Hypogonadal Men) trial, published in the New England Journal of Medicine in 2023.

The TRAVERSE trial was a multicenter, randomized, double-blind, placebo-controlled study involving 5,246 men aged 45 to 80 years with hypogonadism and pre-existing or elevated risk for cardiovascular disease. Participants were randomized to receive either topical testosterone gel vs injections or placebo. The primary outcome was a composite of major adverse cardiovascular events (MACE), including nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes.

The results of the TRAVERSE trial were groundbreaking:

• After a median follow-up of 33 months, the incidence of MACE was not significantly higher in the testosterone group compared to the placebo group.
• The hazard ratio for MACE in the testosterone group versus the placebo group was 0.96 (95% confidence interval, 0.78 to 1.17), indicating no increased risk.

This large-scale, robust trial effectively resolved much of the long-standing debate, demonstrating that TRT, when administered to men with hypogonadism and cardiovascular risk factors, does not increase the risk of major adverse cardiovascular events. This finding has been widely hailed as a pivotal moment in understanding TRT safety.

PMID: 37334136

3. Polycythemia and Hematocrit Elevation

Polycythemia, characterized by an elevated red blood cell count, hemoglobin, and hematocrit, is the most common laboratory abnormality observed in men undergoing TRT.

Mechanism: Testosterone stimulates erythropoiesis (red blood cell production) primarily by increasing renal erythropoietin (EPO) production. This is a physiological effect, as testosterone naturally plays a role in red blood cell regulation.

Typical Ranges and Monitoring:

• Hematocrit (Hct) is the percentage of red blood cells in the blood.
• Normal ranges typically fall between 40-50%.
• Monitoring of hematocrit is crucial during TRT, usually performed at baseline, 3-6 months after initiation, and then annually or as clinically indicated.
• Most clinicians consider a hematocrit level above 52% to be clinically significant, requiring intervention. Levels above 54% are generally considered a contraindication to continuing TRT without intervention.

Clinical Significance: While mild elevations in hematocrit are common and often asymptomatic, excessively high levels (polycythemia) can increase blood viscosity, potentially leading to symptoms such as headache, dizziness, fatigue and low testosterone, and, in rare cases, an increased risk of thrombotic events (e.g., stroke, deep vein thrombosis). However, the direct causal link between TRT-induced erythrocytosis and increased thrombotic events is not as strong as once feared, particularly at levels below 54%.

Management:

• Lowering the testosterone dose.
• Increasing the injection frequency (e.g., from once every two weeks to once weekly) to reduce peak testosterone levels.
• Switching to a different formulation (e.g., topical gel, which tends to cause less hematocrit elevation than injections).
• Therapeutic phlebotomy (blood donation) is an effective and common intervention for persistent, symptomatic, or significantly elevated hematocrit.

A meta-analysis of TRT and polycythemia risk found that testosterone therapy was associated with a significantly increased risk of erythrocytosis, with injectable formulations carrying a higher risk than transdermal preparations. However, the overall incidence of severe, symptomatic polycythemia requiring intervention remains relatively low when therapy is properly monitored.

4. Estrogen Conversion and Gynecomastia

Testosterone is metabolized in the body into several active compounds, including estradiol (E2), a primary estrogen, via the enzyme aromatase. This process, known as aromatization, is a natural physiological pathway.

Gynecomastia, the development of breast tissue in men, is a potential side effect of TRT, primarily due to elevated estrogen levels relative to testosterone, or an absolute increase in estrogen.

When are aromatase inhibitors and alternativess (AIs) Warranted?

• Historically, there was a tendency to routinely prescribe AIs (e.g., anastrozole) alongside TRT to "control" estrogen levels, based on the belief that any elevation was detrimental.
• However, the pendulum has swung significantly against routine AI use. Estrogen plays crucial roles in men's health, including bone mineral density, cardiovascular health, cognitive function, and even libido.
• Optimal estrogen levels are essential, not just low estrogen. Many men on TRT experience elevated estradiol levels within a healthy physiological range without adverse effects.
• AIs are generally only warranted for men who develop clinically significant symptoms of estrogen excess, such as:
  • Gynecomastia: Persistent, painful, or noticeable breast tissue development.
  • Water retention: Excessive fluid retention.
  • Mood swings: In some individuals, very high estrogen can contribute to mood disturbances.
• Over-suppression of estrogen with AIs can lead to its own set of problems, including:
  • Decreased bone mineral density.
  • Reduced libido.
  • Joint pain.
  • Negative impact on lipid profiles.

Current best practice emphasizes monitoring estradiol levels and considering AI use only when symptomatic estrogen excess is present, rather than prophylactic use based solely on elevated numbers.

5. prostate health considerations Health: PSA and BPH

Concerns about TRT's impact on prostate health, particularly the risk of prostate cancer, have been a significant deterrent for many men and clinicians. This fear largely stemmed from observations that prostate cancer cells are often androgen-sensitive, and that castrated men rarely develop prostate cancer.

The longstanding fear of TRT causing prostate cancer has been largely debunked by modern research. Numerous large observational studies, systematic reviews, and meta-analyses have failed to demonstrate a causal link between TRT and an increased risk of developing prostate cancer or worsening pre-existing, undiagnosed prostate cancer.

Key points from the evidence:

• No increased risk of prostate cancer: A comprehensive systematic review on TRT and prostate safety concluded that testosterone therapy does not increase the risk of prostate cancer incidence or recurrence in men with treated prostate cancer.
• PSA Monitoring: Prostate-Specific Antigen (PSA) levels are routinely monitored in men on TRT. A slight, often transient, increase in PSA (typically <0.4 ng/mL) is common during the initial 6-12 months of TRT as the prostate gland reaches its new, larger, but still physiological size. This is generally not indicative of cancer. Significant or sustained increases in PSA warrant further investigation, as they would in any man.
• Benign Prostatic Hyperplasia (BPH): TRT can sometimes exacerbate symptoms of BPH (e.g., urinary frequency, urgency, weak stream) in men with pre-existing, moderate to severe BPH. This is because testosterone can increase prostate volume. However, TRT does not cause BPH, and it typically does not worsen symptoms in men with mild BPH or normal prostate size. Men with severe BPH symptoms are often advised to achieve symptom control before initiating TRT.

**